What Studies Have NOT Demonstrated in Humans Despite community claims, no controlled human trial has demonstrated: A specific body fat percentage reduction attributable to LR3 IGF-1 cycling A specific lean mass gain figure for the standard 10-day-on / 4-week-off pattern Cardiovascular safety endpoints across repeated cycles Long-term cancer-incidence data for cycled LR3 IGF-1 use Epidemiological data on chronically elevated endogenous IGF-1 has raised theoretical cancer concerns (Yoshida & Delafontaine, 2020), and that concern is one reason community protocols favor short, spaced cycles rather than continuous use
There is no official consensus identifying one GLP-1 as definitively 'easiest' on the stomach, as tolerability is highly individual
Back Diem, P, Ducluzeau, PH, Scheen, A (Jan-March 2022) 'The discovery of insulin', Diabetes, Epidemiology and Management , 5, 100049
Popular growth hormone peptides to optimize your levels What are the benefits of optimal growth hormone levels
However, the effectiveness of oral semaglutide depends on closely following the dosing instructions
Upon addition of ME, the olefinic proton (H a ) of TPE-DCV with chemical shift of ~8.4 ppm disappears and a new peak (H b ) at 4.69 ppm arises, suggestive of the addition reaction of thiol on the vinyl group (Figure S6) 58